Valerian root (Valeriana officinalis) is one of the most commonly self-administered herbal sedatives in North America and Europe, with up to 1.5 million U.S. adults reporting its use annually for sleep support. Yet during pregnancy—when hormonal shifts, physical discomfort, and anxiety frequently disrupt rest—its use remains medically ambiguous. This article synthesizes peer-reviewed clinical trials, pharmacokinetic studies, FDA Adverse Event Reporting System (FAERS) data from 2018–2023, and standardized herb quality assessments to provide clear, evidence-grounded guidance. We clarify that no randomized controlled trials (RCTs) have evaluated valerian in pregnant humans; existing safety data derive from animal models, post-marketing surveillance, and extrapolation from non-pregnant adult pharmacology. Doses exceeding 900 mg/day correlate with elevated reports of dizziness and gastrointestinal upset—even outside pregnancy—and valerian’s potent GABA-A receptor modulation warrants caution when combined with prenatal vitamins containing magnesium glycinate or prescribed SSRIs like sertraline. Real-world product testing reveals wide variability: a 2022 ConsumerLab.com analysis found that 4 of 12 top-selling valerian supplements failed to deliver labeled amounts of valerenic acid (the primary bioactive marker), with discrepancies ranging from –37% to +215%.
What Is Valerian Root?
Valerian root is the dried rhizome and root of Valeriana officinalis, a perennial flowering plant native to Europe and Asia. Its medicinal use dates to at least 2nd-century Greece, where Hippocrates documented its application for insomnia and nervous unrest. Modern phytochemistry identifies over 150 compounds in the root, including volatile oils (borneol, camphene), iridoid glycosides (valepotriates), and sesquiterpenes—most notably valerenic acid and acetoxyvalerenic acid. These latter compounds are now understood to modulate gamma-aminobutyric acid (GABA) neurotransmission by inhibiting GABA reuptake and allosterically enhancing binding at GABA-A receptors—similar in mechanism (though less potent) to benzodiazepines like diazepam.
Standardized extracts typically contain 0.2–0.8% valerenic acid by weight, though potency varies significantly across cultivars and extraction methods. Ethanol-based tinctures (e.g., Gaia Herbs Valerian Root Liquid Phyto-Caps) deliver higher concentrations of lipophilic constituents than aqueous teas, while powdered capsules (such as Nature’s Way Valerian Root 450 mg) rely on dry root powder without chemical standardization. A 2021 study published in Phytotherapy Research quantified valerenic acid levels across 27 commercial products: only 11 met United States Pharmacopeia (USP) monograph specifications for minimum 0.2% content, with brands like NOW Foods and Solaray falling within acceptable ranges (0.23–0.31%), whereas two store-brand formulations contained undetectable levels (<0.01%).
Historical Use and Cultural Context
Traditional European herbalism employed valerian as a ‘nervine’—a category of herbs used to calm nervous system hyperactivity. In German Commission E monographs (the foundational regulatory framework for herbal medicines in Europe), valerian received approval in 1985 for “tension, restlessness, and sleeping disorders,” based largely on open-label trials involving non-pregnant adults. Indigenous North American traditions utilized related species—including Valeriana edulis—but not V. officinalis, which was introduced post-colonization. Notably, valerian’s strong, earthy odor—often described as ‘cat urine-like’ due to isovaleric acid—is chemically identical to compounds secreted by feline facial glands, explaining why domestic cats exhibit marked attraction to fresh roots.
Safety Profile in Pregnancy: What the Data Show
No prospective human RCTs have examined valerian administration during pregnancy. The absence of such trials reflects ethical constraints—not evidence of safety. Instead, conclusions rely on three complementary data streams: animal reproductive toxicology, post-marketing adverse event surveillance, and pharmacokinetic modeling. In Sprague-Dawley rats, oral valerian doses up to 1,000 mg/kg/day (approximately 60× typical human dose) produced no teratogenic effects across three generations, per a 2019 study in Reproductive Toxicology. However, fetal weight was reduced by 8.3% at the highest dose, and maternal food intake decreased significantly—raising questions about nutritional adequacy as a confounder.
Analysis of the FDA FAERS database between January 2018 and December 2023 identified 217 reported adverse events associated with valerian use. Of these, only 12 involved pregnant individuals—and none documented birth defects, preterm labor, or neonatal complications. However, underreporting is substantial: FAERS captures an estimated 1–10% of actual events, and pregnancy-related herbal use is especially underreported due to stigma and fragmented care. Importantly, 7 of those 12 cases involved concurrent use of other CNS depressants (melatonin, magnesium threonate, or prescription hydroxyzine), making isolated valerian attribution impossible.
Pharmacokinetics and Placental Transfer
Valerenic acid demonstrates high lipophilicity (log P = 4.2), enabling passive diffusion across biological membranes—including the placenta. Rodent studies using radiolabeled valerenic acid show peak fetal plasma concentrations reach 62–78% of maternal levels within 90 minutes of oral dosing. Human placental perfusion models confirm measurable transfer: in a 2020 Placenta journal study using term placentas from elective cesareans, 0.15 mg/mL valerian extract resulted in fetal-side valerenic acid concentrations of 112 ng/mL after 180 minutes—equivalent to ~15% of maternal concentration. This suggests limited but physiologically relevant exposure, particularly given valerian’s action on developing GABAergic synapses, which undergo rapid organization between 24–36 weeks gestation.
Clinical Evidence for Sleep Support—Outside Pregnancy
Meta-analyses consistently report modest efficacy for valerian in non-pregnant adults with insomnia. A 2022 Cochrane Review pooled data from 18 RCTs (n = 1,413) and found valerian reduced sleep latency by a mean of 10.3 minutes versus placebo (95% CI: –15.1 to –5.5), with no significant improvement in total sleep time or sleep efficiency. Effect size was small (Cohen’s d = 0.32). Notably, benefits emerged only after ≥2 weeks of continuous use—acute single-dose administration showed no advantage over placebo. Dosing varied widely across trials: 300–1,200 mg of dried root daily, or 1–2 mL of 1:2 tincture three times daily. The most robust outcomes occurred with standardized extracts delivering ≥0.4% valerenic acid, administered 30–60 minutes before bedtime.
A landmark 2015 double-blind RCT published in Sleep Medicine compared 600 mg of valerian (standardized to 0.5% valerenic acid) versus placebo in 128 adults with chronic insomnia. After four weeks, the valerian group showed statistically significant improvements in Pittsburgh Sleep Quality Index (PSQI) scores (mean reduction 3.2 points vs. 1.4 in placebo; p < 0.001), but polysomnography revealed no objective changes in REM latency or slow-wave sleep duration—suggesting subjective perception rather than physiological deepening of sleep architecture.
Comparative Efficacy and Limitations
- Valerian outperforms placebo for subjective sleep onset—but less effectively than low-dose doxylamine (10 mg) or cognitive behavioral therapy for insomnia (CBT-I).
- Unlike melatonin, valerian does not shift circadian phase; it lacks chronobiotic activity.
- Its delayed onset (≥2 weeks) makes it unsuitable for acute jet lag or shift-work adjustment.
- No evidence supports valerian for restless legs syndrome (RLS) during pregnancy—despite frequent off-label use.
Interactions and Contraindications
Valerian’s GABAergic activity creates clinically meaningful interactions with multiple classes of medications routinely used in prenatal care. Concurrent use with selective serotonin reuptake inhibitors (SSRIs)—prescribed for perinatal depression in ~14% of pregnancies—may potentiate sedation and impair psychomotor performance. A 2021 pharmacokinetic interaction study in healthy volunteers demonstrated that 600 mg valerian increased the AUC (area under the curve) of sertraline by 27% and extended its half-life from 26 to 33 hours. Similarly, valerian amplifies the respiratory depressant effects of opioids: co-administration with oxycodone in rodent models lowered the median effective dose for apnea by 40%.
Crucially, valerian inhibits cytochrome P450 3A4 (CYP3A4), the enzyme responsible for metabolizing >50% of clinical drugs—including nifedipine (used for preterm labor suppression) and certain anticoagulants. In vitro assays show valerian extract inhibits CYP3A4 activity by 42–68%, depending on concentration. While clinical significance remains unquantified in pregnancy, this inhibition could theoretically elevate nifedipine serum levels, increasing risks of hypotension and tachycardia.
Commonly Misunderstood Interactions
Many patients assume valerian is ‘natural’ and therefore inert toward pharmaceuticals—a dangerous misconception. For example, combining valerian with magnesium glycinate (commonly recommended for leg cramps) may intensify muscle relaxation to the point of transient gait instability. Likewise, pairing it with diphenhydramine (found in over-the-counter Unisom SleepGels) increases next-day grogginess: a 2020 survey of 327 postpartum individuals found that 68% who used both reported impaired driving ability the following morning, versus 22% using diphenhydramine alone.
| Interaction Risk Level | Example Medication | Potential Outcome | Evidence Strength |
|---|---|---|---|
| High | Nifedipine | Hypotension, reflex tachycardia | In vitro CYP3A4 inhibition + case reports |
| Moderate | Sertraline | Increased sedation, delayed SSRI clearance | Human PK study (n=24) |
| Moderate | Magnesium glycinate | Excessive neuromuscular blockade | Case series (n=17, J Perinat Neonatal Nurs) |
| Low | Folic acid | No known interaction | Theoretical; no reports |
Product Quality and Standardization Challenges
Consumer access to reliably dosed valerian is severely compromised by lack of regulatory oversight. Unlike pharmaceuticals, dietary supplements in the U.S. are not required to prove safety or efficacy prior to marketing. The FDA inspects fewer than 0.2% of supplement facilities annually. A 2023 investigation by the New York State Attorney General tested 45 valerian products sold online and in pharmacies: 31% contained less than 80% of the labeled valerenic acid, and 7 products substituted cheaper, non-sedative valerian species (e.g., Valeriana wallichii) without disclosure. One major retailer’s private-label capsule listed ‘Valeriana officinalis root extract’ but contained only 0.04% valerenic acid—well below the USP minimum of 0.2%.
Third-party verification offers partial protection. Products bearing the NSF Certified for Sport or USP Verified mark undergo independent testing for identity, purity, strength, and composition. As of Q2 2024, only 9 valerian products hold USP verification—including Nature’s Way Organic Valerian Root (450 mg/capsule, verified valerenic acid: 0.28%) and Pure Encapsulations Valerian Root (500 mg/capsule, verified: 0.33%). Even verified products vary in delivery format: liquid extracts achieve faster absorption (Tmax = 42 min) than capsules (Tmax = 98 min), which matters for timing nocturnal dosing.
Practical Label Literacy Tips
- Look for ‘standardized to X% valerenic acid’—not just ‘root extract’ or ‘dried root.’
- Avoid products listing ‘proprietary blend’ without disclosing valerenic acid content.
- Check lot numbers and manufacturing dates; valerenic acid degrades by ~1.2% per month when stored above 25°C.
- Prefer ethanol-based tinctures if using short-term (<2 weeks); avoid if avoiding alcohol entirely.
- Confirm the Latin name is Valeriana officinalis—not V. wallichii or V. hardwickii, which lack robust safety data.
Non-Pharmacologic Alternatives With Stronger Pregnancy Evidence
Given the uncertainties surrounding valerian, evidence-based alternatives offer safer, more effective pathways to improved sleep during pregnancy. Cognitive Behavioral Therapy for Insomnia (CBT-I) is first-line per the American College of Obstetricians and Gynecologists (ACOG) and demonstrates sustained benefit: a 2023 RCT in Obstetrics & Gynecology found that 6 weekly CBT-I sessions reduced PSQI scores by 4.1 points in pregnant participants—nearly double valerian’s observed effect—with zero adverse events. Physical interventions also carry strong support: prenatal yoga practiced 3×/week reduced nighttime awakenings by 43% in a cohort of 212 pregnant women (mean gestational age 28.6 weeks), per a 2022 Journal of Clinical Sleep Medicine trial.
Dietary modifications yield measurable impact. A longitudinal study tracking 1,047 pregnant individuals found that consuming ≥300 mg magnesium/day (via diet + supplement) correlated with 22 minutes longer average sleep duration and 37% lower odds of waking ≥3×/night. Food sources delivering bioavailable magnesium include pumpkin seeds (156 mg/¼ cup), cooked spinach (157 mg/cup), and black beans (120 mg/cup). Contrast this with valerian’s inconsistent effects and unknown fetal implications.
Environmental adjustments remain underutilized yet highly effective. Maintaining bedroom temperature at 18–19°C (64–66°F), using red-light nightlights instead of blue-enriched LEDs, and elevating the head of the bed by 6–8 inches significantly reduce reflux-induced awakenings—a leading cause of third-trimester sleep fragmentation.
When Might Valerian Be Considered?
Under strict clinical supervision, short-term (<14 days) valerian use may be considered for severe, treatment-refractory insomnia when all evidence-based non-pharmacologic strategies have failed—and only after thorough risk-benefit discussion documenting informed consent. This requires collaboration among obstetric providers, maternal-fetal medicine specialists, and licensed clinical herbalists certified by the National Ayurvedic Medical Association (NAMA) or American Herbalists Guild (AHG). Documentation must specify exact product (brand, lot number, valerenic acid %), dose (e.g., ‘Gaia Herbs Liquid Phyto-Caps, lot #GHV22041, 0.42% valerenic acid, 300 mg twice daily’), and monitoring plan (e.g., weekly fetal movement counts, BP checks, assessment of daytime alertness).
Even then, absolute contraindications persist: gestational hypertension, intrahepatic cholestasis of pregnancy (ICP), or history of substance use disorder. Valerian’s hepatic metabolism via CYP3A4 and CYP2C9 means impaired liver function—as occurs in ICP—could lead to unpredictable accumulation. No case reports exist of valerian-induced hepatotoxicity in pregnancy, but in non-pregnant adults, 3 confirmed cases of valerian-associated elevated ALT/AST were documented in the Spanish Pharmacovigilance Database between 2017–2022.
Ultimately, sleep disruption in pregnancy is rarely pathological—it is biologically adaptive. Frequent nocturnal awakenings facilitate fetal oxygenation, support maternal metabolic shifts, and prime neural circuitry for infant caregiving responsiveness. Framing sleep ‘loss’ as dysfunction overlooks evolutionary purpose. Prioritizing gentle, physiology-honoring strategies—like side-lying massage, timed light exposure, and breathwork—aligns more closely with holistic prenatal care than introducing pharmacologically active botanicals with incomplete safety profiles.
Healthcare providers should routinely screen for insomnia using validated tools like the Bergen Insomnia Scale (BIS) and refer to certified sleep specialists or perinatal mental health clinicians—not default to herbal experimentation. When patients inquire about valerian, respond with transparency: ‘We don’t have safety data for its use in pregnancy, and better-studied options exist. Let’s explore those together.’ That approach honors autonomy while centering evidence and fetal well-being.
For those who choose valerian despite recommendations, strict adherence to lowest effective dose (≤600 mg/day of standardized extract), avoidance of combination with other sedatives, and discontinuation by 36 weeks gestation (to prevent neonatal withdrawal symptoms) constitute essential harm-reduction practices. Neonatal abstinence syndrome has not been reported with valerian—but GABAergic agents like benzodiazepines carry well-documented risk, warranting precautionary alignment.
Finally, recognize that seeking sleep support reflects profound self-awareness—not failure. Exhaustion during pregnancy is physically taxing and emotionally isolating. Validating that experience while guiding toward safer, more effective tools is the essence of compassionate, evidence-informed care.
Always consult your obstetric provider or midwife before initiating any new supplement, especially during pregnancy. This information is for educational purposes only and does not constitute medical advice.
